Allergic Rhinitis
Conditions
Keywords
allergic rhinitis, moxibustion, body surface temperature
Brief summary
The objective of this randomized controlled clinical trial is to compare the therapeutic effect of moxibustion on allergic rhinitis. The main questions it aims to answer are: Based on randomized controlled trials, verify the effectiveness of moxibustion in treating allergic rhinitis Based on a real-time monitoring system for human surface temperature, discuss the differences in therapeutic effects of different moxibustion doses on allergic rhinitis
Detailed description
Allergic rhinitis has a high incidence and is difficult to cure, seriously affecting the quality of life of patients Compare the effects of different moxibustion durations on the clinical efficacy and body surface temperature of patients with allergic rhinitis, and preliminarily explore the impact of different moxibustion doses on the efficacy of heavy moxibustion treatment for allergic rhinitis, providing evidence-based basis for clinical practice.
Interventions
BEHAVIORALOrdinary moxibustion volume group
Moxibustion for 10 minutes per acupoint
BEHAVIORALFirst group of heavy moxibustion
Moxibustion for 20 minutes per acupoint
BEHAVIORALSecond groups of heavy moxibustion
Moxibustion for 30 minutes per acupoint
Sponsors
Henan University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Those who meet the diagnostic criteria of Chinese and Western medicine for AR; * Age range from 18 to 75 years old, regardless of gender; * Patients and their families are informed and agree to the study.
Exclusion criteria
* Those who are undergoing other traditional Chinese medicine external treatment methods; * Those who have taken traditional Chinese medicine recently or during treatment; * Individuals who are allergic to heavy moxibustion smoke and dust; * Individuals with concomitant bronchial asthma or other respiratory system diseases; * Patients with severe skin diseases or ulcers in the local area where moxibustion is applied; * Pregnant and lactating patients; * Patients with severe diseases of important organs such as the heart, liver, lungs, and kidneys; * Those who are unable to receive treatment according to regulations due to inconvenience in work, study, transportation, or personal activities
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total nasal symptom scores（TNSS） | Change from baseline TNSS scores at week 0(before treatment)，4 and 12. | The main symptoms of allergic rhinitis, the higher the score, the worse the condition |
| Rhinitis VAS Visual Analog Scale（AR-VAS） | Change from baseline VAS scores at week 0(before treatment)，4 and 12. | VAS will be used to evaluate the relief of rhinitis symptoms, with a total score of 0-10. The higher the score, the more severe the symptoms will be |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total non nasal symptom scores（TNNSS） | Change from baseline TNNSS scores at week0(before treatment)，4 and 12. | The nasal accompanying symptoms of allergic rhinitis, qualitative evaluation of the severity of the disease, with some indicating severity and none indicating milder severity |
| Rhino-conjunctivitis Quality of Life Questionnaire （RQLQ） | Change from baseline RQLQ scores at week0(before treatment)，4 and 12. | RQLQ consists of 28 items, including daily life (1-3), sleep (4-6), non nasal eye symptoms (7-13), life problems (14-16), nasal symptoms (17-20), eye symptoms (21-24), and emotions (25-28). In the 7-point system, 1 point is the best and 7 points are the worst. |
| Detection of serum IgE and IL-33 levels | Week0(before treatment), week 4（after treatment）. | Immunoglobulin IgE and serum inflammatory cytokine IL-33 levels |
Countries
China
Contacts
Primary ContactYang Xie, MD
Outcome results
None listed